<?xml version="1.0" encoding="UTF-8"?><document pubDate="1396441335">	<riskgroups>        <rgcontainer id="1">            <rg>Low Risk</rg>            <scs>                <sc><![CDATA[A]]></sc>            </scs>        </rgcontainer>        <rgcontainer id="2">            <rg>Intermediate Risk</rg>            <scs>                <sc><![CDATA[B2]]></sc>                <sc><![CDATA[B1]]></sc>            </scs>        </rgcontainer>        <rgcontainer id="3">            <rg>High Risk</rg>            <scs>                <sc><![CDATA[C]]></sc>            </scs>        </rgcontainer>        <rgcontainer id="4">            <rg>Highest Risk</rg>            <scs>                <sc><![CDATA[D]]></sc>                <sc><![CDATA[D*]]></sc>            </scs>        </rgcontainer>    </riskgroups>    <patterns>        <pattern>            <scheme><![CDATA[A]]></scheme>            <tumorentity><![CDATA[Non-muscle invasive bladdercancer]]></tumorentity>            <riskgroup><![CDATA[Low Risk]]></riskgroup>            <decision><![CDATA[]]></decision>            <radicalcystectomy><![CDATA[0]]></radicalcystectomy>            <turbt>1</turbt>            <earlychemotherapyinstillation>1</earlychemotherapyinstillation>            <earlychemotherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[Mitomycin]]></earlychemotherapysubstance>            <earlychemotherapydosage><![CDATA[40 mg]]></earlychemotherapydosage>            <adjuvanttherapysubstance><![CDATA[n.a.]]></adjuvanttherapysubstance>            <adjuvanttherapydosage><![CDATA[n.a.]]></adjuvanttherapydosage>            <inductiontherapy>0</inductiontherapy>            <maintenancetherapy>1</maintenancetherapy>            <inductiontherapyschedule><![CDATA[n.a.]]></inductiontherapyschedule>            <maintenancetherapyschedule><![CDATA[n.a.]]></maintenancetherapyschedule>            <literature1><![CDATA[Kaasinen E, Rintala E, Hellstrom P, et al; FinnBladder Group. Factors explaining recurrence in patients undergoing chemo-immunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002 Aug;42(2):167-74.]]></literature1>            <link1><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/12160589]]></link1>            <literature2><![CDATA[Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004 Jun;171(6 Pt 1):2186-90.]]></literature2>            <link2><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15126782]]></link2>        </pattern>        <pattern>            <scheme><![CDATA[B1]]></scheme>            <tumorentity><![CDATA[Non-muscle invasive bladdercancer]]></tumorentity>            <riskgroup><![CDATA[Intermediate Risk]]></riskgroup>            <decision><![CDATA[Lower Therapy Toxicity]]></decision>            <radicalcystectomy><![CDATA[0]]></radicalcystectomy>            <turbt>1</turbt>            <earlychemotherapyinstillation>1</earlychemotherapyinstillation>            <earlychemotherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[Mitomycin]]></earlychemotherapysubstance>            <earlychemotherapydosage><![CDATA[40 mg]]></earlychemotherapydosage>            <adjuvanttherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[Mitomycin]]></adjuvanttherapysubstance>            <adjuvanttherapydosage><![CDATA[40 mg]]></adjuvanttherapydosage>            <inductiontherapy>1</inductiontherapy>            <maintenancetherapy>1</maintenancetherapy>            <inductiontherapyschedule><![CDATA[1 instillation per week for 8 weeks; week 4-11 after TURBT]]></inductiontherapyschedule>            <maintenancetherapyschedule><![CDATA[1 instillation per month for 1 month; month 4-12 after TURBT]]></maintenancetherapyschedule>            <literature1><![CDATA[Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001 Jan-Feb;21(1B):765-9.]]></literature1>            <link1><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/11299841]]></link1>            <literature2><![CDATA[Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non muscle invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008 Apr;53(4):709-19.]]></literature2>            <link2><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/18207317]]></link2>        </pattern>        <pattern>            <scheme><![CDATA[B2]]></scheme>            <tumorentity><![CDATA[Non-muscle invasive bladdercancer]]></tumorentity>            <riskgroup><![CDATA[Intermediate Risk]]></riskgroup>            <decision><![CDATA[Lower Recurrence Risk]]></decision>            <radicalcystectomy><![CDATA[0]]></radicalcystectomy>            <turbt>1</turbt>            <earlychemotherapyinstillation>1</earlychemotherapyinstillation>            <earlychemotherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[Mitomycin]]></earlychemotherapysubstance>            <earlychemotherapydosage><![CDATA[40 mg]]></earlychemotherapydosage>            <adjuvanttherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[BCG]]></adjuvanttherapysubstance>            <adjuvanttherapydosage><![CDATA[n.a.]]></adjuvanttherapydosage>            <inductiontherapy>1</inductiontherapy>            <maintenancetherapy>1</maintenancetherapy>            <inductiontherapyschedule><![CDATA[1 instillation per week for 6 weeks; week 2-7 after TURBT]]></inductiontherapyschedule>            <maintenancetherapyschedule><![CDATA[1 instillation per week for 3 weeks; at months 3, 6 and 12 after TURBT]]></maintenancetherapyschedule>            <literature1><![CDATA[Malmström P-U, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the longterm outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009 Aug;56(2):247-56.]]></literature1>            <link1><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19409692]]></link1>            <literature2><![CDATA[Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003 Jan;169(1):90-5.]]></literature2>            <link2><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/12478111]]></link2>        </pattern>        <pattern>            <scheme><![CDATA[C]]></scheme>            <tumorentity><![CDATA[Non-muscle invasive bladdercancer]]></tumorentity>            <riskgroup><![CDATA[High Risk]]></riskgroup>            <decision><![CDATA[]]></decision>            <radicalcystectomy><![CDATA[0]]></radicalcystectomy>            <turbt>1</turbt>            <earlychemotherapyinstillation>1</earlychemotherapyinstillation>            <earlychemotherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[Mitomycin]]></earlychemotherapysubstance>            <earlychemotherapydosage><![CDATA[40 mg]]></earlychemotherapydosage>            <adjuvanttherapysubstance link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[BCG]]></adjuvanttherapysubstance>            <adjuvanttherapydosage><![CDATA[n.a.]]></adjuvanttherapydosage>            <inductiontherapy>1</inductiontherapy>            <maintenancetherapy>1</maintenancetherapy>            <inductiontherapyschedule><![CDATA[1 instillation per week for 6 weeks; week 2-7 after TURBT]]></inductiontherapyschedule>            <maintenancetherapyschedule><![CDATA[1 instillation per week for 3 weeks; at months 3, 6, 12, 18, 24 and 36 after TURBT]]></maintenancetherapyschedule>            <literature1><![CDATA[Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guérin is superior to in reducing tumour recurrence in high-risk superficial bladder cancer: a metaanalysis of mitomycin C randomized trials. BJU Int 2004 Mar;93(4):485-90.]]></literature1>            <link1><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/15008714]]></link1>            <literature2><![CDATA[Oddens J, Brausi M, Sylvester R, et al. Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. Eur Urol 2013 Mar;63(3):462-72.]]></literature2>            <link2><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/23141049]]></link2>        </pattern>        <pattern>            <scheme><![CDATA[D]]></scheme>            <tumorentity><![CDATA[Non-muscle invasive bladdercancer]]></tumorentity>            <riskgroup><![CDATA[Highest Risk]]></riskgroup>            <decision link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[BCG Naive/Susceptible]]></decision>            <radicalcystectomy><![CDATA[should be considered]]></radicalcystectomy>            <turbt>0</turbt>            <earlychemotherapyinstillation>0</earlychemotherapyinstillation>            <earlychemotherapysubstance><![CDATA[n.a.]]></earlychemotherapysubstance>            <earlychemotherapydosage><![CDATA[n.a.]]></earlychemotherapydosage>            <adjuvanttherapysubstance><![CDATA[n.a.]]></adjuvanttherapysubstance>            <adjuvanttherapydosage><![CDATA[n.a.]]></adjuvanttherapydosage>            <inductiontherapy>0</inductiontherapy>            <maintenancetherapy>0</maintenancetherapy>            <inductiontherapyschedule><![CDATA[n.a.]]></inductiontherapyschedule>            <maintenancetherapyschedule><![CDATA[n.a.]]></maintenancetherapyschedule>            <literature1><![CDATA[Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression inindividual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 Mar;49(3):466-5.]]></literature1>            <link1><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/16442208]]></link1>            <literature2><![CDATA[Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009 Nov;182(5):2195-203.]]></literature2>            <link2><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/19758621]]></link2>        </pattern>        <pattern>            <scheme><![CDATA[D*]]></scheme>            <tumorentity><![CDATA[Non-muscle invasive bladdercancer]]></tumorentity>            <riskgroup><![CDATA[Highest Risk]]></riskgroup>            <decision link="http://international.medac.de/medac_international/relaunch/t_sec.htm"><![CDATA[BCG Refractory]]></decision>            <radicalcystectomy><![CDATA[is recommended]]></radicalcystectomy>            <turbt>0</turbt>            <earlychemotherapyinstillation>0</earlychemotherapyinstillation>            <earlychemotherapysubstance><![CDATA[n.a.]]></earlychemotherapysubstance>            <earlychemotherapydosage><![CDATA[n.a.]]></earlychemotherapydosage>            <adjuvanttherapysubstance><![CDATA[n.a.]]></adjuvanttherapysubstance>            <adjuvanttherapydosage><![CDATA[n.a.]]></adjuvanttherapydosage>            <inductiontherapy>0</inductiontherapy>            <maintenancetherapy>0</maintenancetherapy>            <inductiontherapyschedule><![CDATA[n.a.]]></inductiontherapyschedule>            <maintenancetherapyschedule><![CDATA[n.a.]]></maintenancetherapyschedule>            <literature1><![CDATA[Raj GV, Herr H, Serio AM, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007 Apr;177(4):1283-6.]]></literature1>            <link1><![CDATA[http://www.ncbi.nlm.nih.gov/pubmed/17382713]]></link1>            <literature2><![CDATA[]]></literature2>            <link2><![CDATA[]]></link2>        </pattern>    </patterns></document>